GlassScriptPhysician profile
Carlos A Alvarez
NPI 1023183282
$11,899.11
in general payments reported to CMS, 2019-2025
60 companies · $1,868 in 2025
The $1,868 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,992 · 2022: $2,606 · 2023: $2,356 · 2024: $2,077 · 2025: $1,868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,227 · Education: $74.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,226.80 |
| Education | $74.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,532.82 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Corcept Therapeutics | $1,524.92 | 2021-2025 | Korlym |
| Novo Nordisk INC | $1,444.48 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,121.58 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $648.41 | 2021-2025 | |
| Glaxosmithkline, LLC. | $549.07 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Radius Health, INC. | $495.55 | 2021-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $428.29 | 2021-2025 | Jardiance, Synjardy |
| Amgen INC. | $325.04 | 2021-2025 | Repatha, Otezla, Tepezza |
| Pfizer INC. | $230.89 | 2021-2024 | |
| Abbott Laboratories | $226.82 | 2021-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $199.02 | 2024-2025 | Veozah, Cresemba |
| Antares Pharma, INC. | $191.15 | 2023-2025 | Xyosted, Tlando |
| Amarin Pharma, INC. | $177.72 | 2021 | |
| Xeris Pharmaceuticals, INC. | $167.03 | 2022-2025 | Gvoke Hypopen |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $155.76 | 2021-2023 | Afrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $149.50 | 2021-2025 | Trintellix |
| Recordati_rare_diseases_inc. | $148.27 | 2022-2025 | Isturisa |
| Sanofi-Aventis U.S. LLC | $142.47 | 2021-2023 | |
| Shield Therapeutics INC | $132.32 | 2023-2025 | Accrufer |
| Halozyme INC | $107.21 | 2023 | |
| Merck Sharp & Dohme LLC | $104.93 | 2022-2023 | Verquvo, Steglatro, Belsomra |
| Phathom Pharmaceuticals, INC. | $94.73 | 2024-2025 | Voquezna |
| Medtronic, INC. | $77.90 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $77.13 | 2021-2024 | |
| Insulet Corporation | $74.10 | 2021 | |
| Glaukos Corporation | $71.14 | 2025 | Kxl System (Not Refurbished) |
| Eusa Pharma (US) LLC | $70.73 | 2022 | |
| Dexcom, INC. | $70.68 | 2021-2024 | Dexcom G6 Transmitter |
| Ascendis Pharma Endocrinology INC | $69.88 | 2024-2025 | Yorvipath |
| Exact Sciences Corporation | $69.46 | 2023-2024 | Cologuard Collection Kit |
| Amryt Pharma Holdings LTD | $69.37 | 2022-2023 | Mycapssa |
| Tandem Diabetes Care, INC. | $68.14 | 2022-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Bausch Health US, LLC | $67.44 | 2025 | Aplenzin, Wellbutrin |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.93 | 2021-2023 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $63.34 | 2021 | |
| Zealand Pharma US, INC. | $62.41 | 2021-2022 | |
| Ascensia Diabetes Care US INC. | $58.40 | 2023-2024 | |
| Idorsia Pharmaceuticals US INC | $55.26 | 2022-2023 | Quviviq |
| Nevro Corp. | $52.00 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $47.30 | 2025 | |
| Baxter Healthcare | $40.27 | 2023-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Viiv Healthcare Company | $30.62 | 2025 | Apretude |
| Arbor Pharmaceuticals, INC. | $29.80 | 2021 | |
| Almatica Pharma LLC | $28.18 | 2022 | |
| Madrigal Pharmaceuticals | $26.73 | 2025 | Rezdiffra |
| Chiesi USA, INC. | $25.84 | 2025 | Mycapssa |
| Averitas Pharma INC. | $25.68 | 2024 | Qutenza |
| Abiomed | $24.75 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $24.29 | 2025 | |
| Daiichi Sankyo INC. | $22.60 | 2022 | |
| Kyowa Kirin, INC. | $22.29 | 2023 | Crysvita |
| Eisai INC. | $20.52 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $15.01 | 2024 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $14.77 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.84 | 2022 | |
| Horizon Therapeutics Plc | $13.24 | 2023 | Tepezza |
| Agile Therapeutics, INC. | $12.69 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $11.25 | 2021 | |
| Genentech USA, INC. | $7.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.